Avista Pharma acquisition finalized

LONGMONT — The acquisition of Avista Pharma Solutions Inc., a pharmaceutical ingredient manufacturing company with a major Longmont presence, by Cambrex Corp. (NYSE: CBM) closed this week.

As a result of the $252-million deal, first announced in November, New Jersey-based Cambrex, a generic active pharmaceutical ingredient maker, has strengthened its position as a fully integrated small molecule contract development and manufacturing organization across the drug lifecycle, according to a company news release.

“Acquiring Avista adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for both…